Media stories about DexCom (NASDAQ:DXCM) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DexCom earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 46.5974631310066 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Several research firms have weighed in on DXCM. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price target (down previously from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Raymond James Financial, Inc. downgraded DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. Canaccord Genuity reaffirmed a “buy” rating and issued a $69.00 price objective (down previously from $90.00) on shares of DexCom in a research report on Thursday, September 28th. TheStreet downgraded DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. Finally, ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $70.69.

Shares of DexCom (DXCM) traded up $0.99 on Friday, hitting $54.01. The company’s stock had a trading volume of 1,530,519 shares, compared to its average volume of 1,625,928. DexCom has a 12 month low of $42.62 and a 12 month high of $88.80. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

In other DexCom news, Director Steven R. Altman purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were acquired at an average price of $49.61 per share, for a total transaction of $496,100.00. Following the completion of the purchase, the director now owns 4,353 shares in the company, valued at approximately $215,952.33. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $69.34, for a total value of $416,040.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,964 shares of company stock worth $948,039. 1.70% of the stock is currently owned by insiders.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/19/dexcom-dxcm-getting-somewhat-positive-press-coverage-study-finds.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.